Cover Image

Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada

Daniel T Grima1, Stephen T Brown1, Laveena Kamboj2, Kevin R Bainey3, Ron Goeree4,5, Paul Oh6, Krishnan Ramanathan7, Shaun G Goodman81Cornerstone Research Group, Burlington, ON, 2AstraZeneca Canada, Mississauga, ON, 3Mazankowski Alberta Heart Institute/University of Alberta Hospital, Edmonton, AB, 4P...

Full description

Saved in:

Bibliographic Details
Main Authors:	Grima DT (Author), Brown ST (Author), Kamboj L (Author), Bainey KR (Author), Goeree R (Author), Oh P (Author), Ramanathan K (Author), Goodman SG (Author)
Format:	Book
Published:	Dove Medical Press, 2014-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain
by: E. Molina-Cuadrado, et al.
Published: (2014)

Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes
by: Peixun He, et al.
Published: (2021)

Ticagrelor versus clopidogrel in the management of acute myocardial infarction
by: Candice Volney, et al.
Published: (2019)

Comparison of Ticagrelor and Clopidogrel for Patients Undergoing Emergency Percutaneous Coronary Intervention
by: Bin YANG, et al.
Published: (2018)

Ticagrelor versus clopidogrel for recurrent myocardial infarction: An outcomes-based agreement
by: Samuel K. Peasah, et al.
Published: (2023)

Efficacy and safety outcomes of ticagrelor compared with clopidogrel in Chinese elderly patients with acute coronary syndrome
by: Wang HD, et al.
Published: (2016)

In silico Investigation on Clopidogrel, Prasugrel and Ticagrelor as Potential Mono Antiplatelet Therapy for Acute Coronary Syndrome
by: Muhammad Naufal Hibatullah, et al.
Published: (2024)

Coronary artery bypass grafting on clopidogrel or ticagrelor therapy: interval of discontinuation and risk of bleeding
by: Paolo Nardi, et al.
Published: (2020)

Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis
by: Fan ZG, et al.
Published: (2019)

Comparison of Efficacy between Clopidogrel and Ticagrelor in Patients with Acute Coronary Syndrome after Interventional Treatment and Their Effects on IL-6
by: Bin YANG, et al.
Published: (2020)

Comparison of Safety and Efficacy Between Clopidogrel and Ticagrelor in Elderly Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
by: Xiangkai Zhao, et al.
Published: (2021)

INFLUENCE OF SWITCHING OF CLOPIDOGREL TO TICAGRELOR ON THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ST SEGMENT ELEVATION
by: E. V. Tavlueva, et al.
Published: (2017)

Critical appraisal of ticagrelor in the management of acute coronary syndrome
by: Nawarskas JJ, et al.
Published: (2011)

Comparison of Ticagrelor with Clopidogrel in Reducing Interleukin-17 and Myeloperoxidase Expression in Thrombus and Improving Postprocedural Coronary Flow in ST-segment Elevation Myocardial Infarction Patients
by: WenHua Li, et al.
Published: (2018)

PLACE OF TICAGRELOR IN THE NEW RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME
by: A. D. Ehrlich
Published: (2015)

Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS
by: Shu Tang, et al.
Published: (2022)

The Effect of Clopidogrel and Ticagrelor on Human Adipose Mesenchymal Stem Cell Osteogenic Differentiation Potential: In Vitro Comparative Study
by: Sally S. Mohamed, et al.
Published: (2024)

Randomized evaluation of the loss‐of‐function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics
by: Joshua P. Lewis, et al.
Published: (2024)

Ticagrelor after Acute Coronary Syndrome: One For All or Part of Personalized Medicine?
by: Ibrahim Akin, et al.
Published: (2022)

Determinants to optimize response to clopidogrel in acute coronary syndrome
by: Betti Giusti, et al.
Published: (2010)

The role of clopidogrel in the current treatment of acute coronary syndrome
by: I. S. Yavelov
Published: (2020)

SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
by: Tingting Ma, et al.
Published: (2022)

Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials
by: Pravesh Kumar Bundhun, et al.
Published: (2017)

Effect of preoperative loading dose ticagrelor and clopidogrel on no-reflow phenomenon during intervention in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis
by: Dai W, et al.
Published: (2018)

Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark
by: Pernille Gro Thrane, et al.
Published: (2022)

Current views on antiplatelet therapy in acute coronary syndrome patients: the place of clopidogrel
by: O. O. Shakhmatova
Published: (2022)

Cost-effectiveness and cost-utility analysis of the use of clopidogrel and pantoprazole in comparison with clopidogrel and omeprazole for the secondary prevention of myocardial infarction in Iran
by: Mohammadreza Amirsadri, et al.
Published: (2021)

EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: A. L. Alyavi, et al.
Published: (2016)

EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: A. L. Alyavi, et al.
Published: (2016)

Inflammatory and Antioxidant Pattern Unbalance in "Clopidogrel-Resistant" Patients during Acute Coronary Syndrome
by: Raffaele Caruso, et al.
Published: (2015)

Economic Evaluation of Ticagrelor Plus Aspirin Versus Aspirin Alone for Acute Ischemic Stroke and Transient Ischemic Attack
by: Jigang Chen, et al.
Published: (2022)

Identification of Potential Biological Factors Affecting the Treatment of Ticagrelor After Percutaneous Coronary Intervention in the Chinese Population
by: Yuan D, et al.
Published: (2022)

NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: K. B. Mirzaev, et al.
Published: (2018)

Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats
by: Jia Chong, et al.
Published: (2020)

Investigation of Solubility Enhancement Approaches of Ticagrelor
by: Ihsan A. Mohammed, et al.
Published: (2018)

The Effect of Platelet Activity, ABCB1 Genetic Polymorphism, and Renal Function on the Development of Ticagrelor-Related Dyspnea in Patients with Acute Coronary Syndrome
by: Tamakauskas V, et al.
Published: (2024)

Musk Tongxin Dripping Pills for treating Ticagrelor in Patients After Percutaneous Coronary Intervention: Echocardiography Combined with Untargeted Metabolomics
by: Lyu Nan, et al.
Published: (2021)

Influence of CYP450 Enzymes and ABCB1 Polymorphisms on Clopidogrel Response in Moroccan Patients with Acute Coronary Syndromes
by: Mouhrach I, et al.
Published: (2023)

RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
by: V. A. Sulimov, et al.
Published: (2015)

RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
by: V. A. Sulimov, et al.
Published: (2015)